CSL Ltd shares rebound 86% following FY26 results

CSL Ltd shares have experienced a significant recovery, rebounding 86% from a multi-year low reached in early June. The biotech company's stock has also risen approximately 38% over the past month.

The rebound follows the company's FY26 financial results reported in mid-August, which included total revenue of US$15.8 billion and a net profit after tax of US$2.6 billion. While the company recorded a net loss after tax of US$2.6 billion due to pre-tax impairments and restructuring costs, management characterized the period as a ‘reset year’ with expectations for a return to growth in FY27.

Investor sentiment appears to be shifting as Australian healthcare stocks recover, with the S&P/ASX 200 Health Care Index rising more than 20% in a recent month.